Ariel Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$219M Buy
785,961
+21,289
+3% +$6.13M 2.45% 16
2025
Q4
$232M Sell
764,672
-44,808
-6% -$14M 2.5% 15
2025
Q3
$227M Sell
809,480
-9,144
-1% -$2.49M 2.43% 15
2025
Q2
$198M Buy
818,624
+93,964
+13% +$22.2M 2.24% 16
2025
Q1
$176M Buy
724,660
+164,136
+29% +$49.4M 2.07% 20
2024
Q4
$184M Buy
560,524
+181,829
+48% +$61.7M 1.96% 24
2024
Q3
$127M Buy
378,695
+274,508
+263% +$87.2M 1.29% 35
2024
Q2
$28.5M Buy
104,187
+39,095
+60% +$11.4M 0.31% 75
2024
Q1
$22.5M Buy
65,092
+60,615
+1,354% +$19.9M 0.22% 81
2023
Q4
$1.45M Sell
4,477
-52
-1% -$16.3K 0.01% 104
2023
Q3
$1.62M Buy
4,529
+136
+3% +$52.5K 0.02% 104
2023
Q2
$1.67M Sell
4,393
-27,404
-86% -$11.2M 0.02% 106
2023
Q1
$15.2M Sell
31,797
-99
-0.3% -$46.3K 0.15% 83
2022
Q4
$13.4M Sell
31,896
-34,769
-52% -$14M 0.14% 81
2022
Q3
$27.8M Buy
66,665
+2,762
+4% +$1.38M 0.31% 70
2022
Q2
$31.6M Buy
63,903
+2,167
+4% +$1.13M 0.32% 69
2022
Q1
$34.8M Buy
61,736
+5,986
+11% +$3.61M 0.31% 71
2021
Q4
$42.1M Buy
55,750
+3,810
+7% +$2.85M 0.36% 70
2021
Q3
$38.7M Sell
51,940
-194
-0.4% -$145K 0.35% 71
2021
Q2
$33.6M Buy
52,134
+833
+2% +$507K 0.32% 71
2021
Q1
$29.3M Buy
51,301
+1,990
+4% +$1.18M 0.29% 77
2020
Q4
$28.7M Sell
49,311
-15,082
-23% -$8.59M 0.32% 70
2020
Q3
$33.2M Sell
64,393
-8,293
-11% -$4.2M 0.48% 56
2020
Q2
$32.8M Sell
72,686
-86,128
-54% -$38M 0.5% 55
2020
Q1
$55.7M Sell
158,814
-67,684
-30% -$24.9M 0.98% 34
2019
Q4
$83.8M Buy
226,498
+2,326
+1% +$820K 1.05% 36
2019
Q3
$74.6M Sell
224,172
-7,146
-3% -$2.33M 0.99% 38
2019
Q2
$72.3M Sell
231,318
-9,031
-4% -$2.7M 0.91% 45
2019
Q1
$73.5M Buy
240,349
+16,011
+7% +$4.32M 0.91% 41
2018
Q4
$52.1M Sell
224,338
-8,323
-4% -$2.23M 0.73% 51
2018
Q3
$72.8M Buy
232,661
+685
+0.3% +$213K 0.81% 44
2018
Q2
$66.9M Sell
231,976
-19,153
-8% -$5.29M 0.75% 52
2018
Q1
$62.8M Sell
251,129
-16,391
-6% -$4.17M 0.72% 54
2017
Q4
$63.8M Sell
267,520
-256,724
-49% -$62.2M 0.72% 51
2017
Q3
$116M Sell
524,244
-49,993
-9% -$11.3M 1.35% 23
2017
Q2
$130M Sell
574,237
-100,123
-15% -$21.8M 1.54% 20
2017
Q1
$134M Sell
674,360
-212,467
-24% -$40.9M 1.58% 20
2016
Q4
$162M Sell
886,827
-71,219
-7% -$12.1M 1.91% 10
2016
Q3
$157M Sell
958,046
-22,805
-2% -$3.46M 1.9% 11
2016
Q2
$140M Sell
980,851
-23,641
-2% -$3.37M 1.76% 13
2016
Q1
$137M Sell
1,004,492
-1,455
-0.1% -$191K 1.65% 17
2015
Q4
$139M Buy
1,005,947
+5,786
+0.6% +$802K 1.67% 17
2015
Q3
$134M Sell
1,000,161
-122,822
-11% -$17.7M 1.67% 14
2015
Q2
$169M Sell
1,122,983
-18,159
-2% -$2.6M 1.9% 12
2015
Q1
$154M Buy
1,141,142
+80,575
+8% +$9.99M 1.73% 14
2014
Q4
$128M Sell
1,060,567
-6,659
-0.6% -$766K 1.48% 20
2014
Q3
$121M Buy
1,067,226
+83,774
+9% +$9.93M 1.56% 21
2014
Q2
$118M Sell
983,452
-41,277
-4% -$5.04M 1.44% 21
2014
Q1
$131M Sell
1,024,729
-77,878
-7% -$9.98M 1.6% 18
2013
Q4
$136M Buy
1,102,607
+5,994
+0.5% +$730K 1.67% 18
2013
Q3
$129M Buy
1,096,613
+84,207
+8% +$9.93M 1.88% 14
2013
Q2
$114M Buy
+1,012,406
New +$119M 1.86% 16

Other funds holding BIO

Ariel Investments's BIO Position: Q1 2026 in Review

Ariel Investments increased its Bio-Rad Laboratories Class A (BIO) stake by 2.8% in Q1 2026, buying an estimated $6.13M and bringing the position to 785,961 shares worth $219M. The position accounts for 2.45% of the portfolio, ranked #16.

Ariel Investments first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $232M in Q4 2025. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Ariel Investments held 785,961 shares of Bio-Rad Laboratories Class A worth $219M as of Q1 2026.
  • Ariel Investments bought 21,289 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $6.13M.
  • Bio-Rad Laboratories Class A made up 2.45% of Ariel Investments's portfolio in Q1 2026, its #16 holding.
  • Ariel Investments first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
  • Ariel Investments's Bio-Rad Laboratories Class A position peaked at $232M in Q4 2025.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Ariel Investments's 13F filing for Q1 2026, filed 14 May 2026.